Robert Hershberg
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Recursion Pharmaceuticals Stock Falls as Cathie Wood Adjusts Biotech Holdings. Recursion Pharmaceuticals shares have declined recently while the broader market improved. This movement coincides with Cathie Wood's recent portfolio adjustments, where she increased positions in several biotech stocks while reducing others. The stock is currently trading near the middle of its 52-week range, with analysts maintaining an average target price of $7.22.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Transaction History
| ADPT | ▲ Buy | Option Exercise | 15,000 | $95K | 8/18/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 15,000 | $366K | 8/18/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 15,664 | $382K | 8/18/2026 | View on chart |
| RXRX | ▲ Buy | Grant | 88,424 | $0 | 6/17/2026 | View on chart |
| ADPT | ▲ Buy | Grant | 15,625 | $0 | 3/4/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 22,968 | $367K | 12/10/2025 | View on chart |
| RXRX | ▲ Buy | Grant | 22,016 | $0 | 6/18/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 53,000 | $402K | 3/12/2025 | View on chart |
| ADPT | ▲ Buy | Grant | 15,394 | $0 | 3/4/2025 | View on chart |
| RXRX | ▲ Buy | Grant | 13,097 | $0 | 6/3/2024 | View on chart |
| ADPT | ▲ Buy | Grant | 31,328 | $0 | 3/4/2024 | View on chart |
| RXRX | ▲ Buy | Grant | 12,612 | $0 | 6/16/2023 | View on chart |
| ADPT | ▲ Buy | Grant | 14,775 | $0 | 3/6/2023 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 53,000 | $24K | 2/2/2023 | View on chart |
| RXRX | ▲ Buy | Grant | 18,145 | $0 | 6/14/2022 | View on chart |
| FATE | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 672 | $15K | 6/3/2022 | View on chart |
| ADPT | ▲ Buy | Grant | 6,689 | $0 | 1/26/2022 | View on chart |
| RXRX | ▲ Buy | Grant | 693 | $0 | 1/3/2022 | View on chart |
| RXRX | ▲ Buy | Grant | 572 | $0 | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.